SYDNEY: Anagenics Limited (ASX: AN1) has appointed Matthew Dudek as Acting Chief Executive Officer, effective 28 February 2022. Maria Halasz has resigned as CEO and Managing Director of Anagenics Limited, effective on the same date.
Matthew has been the Company’s Group Financial Controller since the beginning of 2020. He is a graduate from the University of Sydney, B.Com (Accounting, Finance and Economics) and is a member of Chartered Accountants Australia and New Zealand. Since joining Anagenics Matthew has played a key role in the day-to-day management of the Company, has a deep knowledge of the business and a strong track record in implementing profit improvement initiatives and strategies.
Matthew will continue to be supported by a highly qualified senior executive team including Dr Dominic Burg as Chief Operating Officer and Carolyn Heath as General Manager Sales.
The priority of the Company is to build a profitable foundation by implementing near term cost optimization measures and, in parallel, capitalise on the growth potential of its technology, eCommerce and brands by pursuing a pipeline of white label partnerships and distribution opportunities.
“I am honoured to take over as Chief Executive Officer. Anagenics is an exciting company with strong intellectual property, highly differentiated products and global potential. I am looking forward to delivering on our objectives and leading our next stage of growth” said incoming CEO, Matthew Dudek.
“I am delighted to have a strong internal appointment and would like to welcome Matthew, on behalf of the Board, in his new role. I look forward to supporting him in delivering the Company to near term profitability” said Chairman Sandy Beard.
Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary brands of differentiated, clinically validated anti-aging and solutions and the exclusive distribution of Australian and international cosmeceutical and wellness brands.